ArticleThe Proceedings of the Nutrition Society2020
Linking epidemiology and molecular mechanisms in sarcopenic obesity in populations.
Article in The Proceedings of the Nutrition Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A nomogram model for identifying cognitive frailty in elderly patients with chronic diseases: a multicenter cross-sectional study.Frontiers in public health · 2026Observational
- Adipose tissue distribution in metabolic disease: depot-specific biology, clinical assessment, and therapeutic remodeling.Frontiers in endocrinology · 2026Review
- L-shaped association between lean body mass to visceral fat mass ratio with hyperuricemia: a cross-sectional study.Lipids in health and disease · 2024Article
- Sarcopenic obesity: emerging mechanisms and therapeutic potential.Metabolism: clinical and experimental · 2023Review
- Metabolic Impact of Frailty Changes Diabetes Trajectory.Metabolites · 2023Review
- Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of cardiometabolic diseases in a Chinese natural population: A cross-sectional study.Diabetes/metabolism research and reviews · 2023Article
- GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Lifetime body mass index and grip strength at age 46 years: the 1970 British Cohort Study.Journal of cachexia, sarcopenia and muscle · 2022Article
- FGF19 protects skeletal muscle against obesity-induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT-1/PGC-α pathway.Journal of cellular and molecular medicine · 2021Article
- The Critical Role of Oxidative Stress in Sarcopenic Obesity.Oxidative medicine and cellular longevity · 2021Review
- Health Consequences of Sarcopenic Obesity: A Narrative Review.Frontiers in endocrinology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Recognising the adverse outcomes that occur to obese adults over the age of 65 years with loss of muscle mass or strength, or sarcopenia is important. We will review the definitions of sarcopenic obesity, and attempt to link the epidemiological data with the molecular pathways. Upon understanding the model of sarcopenic obesity, we will discuss targeted interventions and further challenges to address this geriatric syndrome. As our understanding of this syndrome is growing, more data are emerging to help define sarcopenic obesity across different populations. We now have a better understanding of biological pathways in ageing such as changes in body composition, sex-specific hormones, pro-inflammatory markers and myocellular mechanisms. We will review a comprehensive model that shows the interactions between the different pathways leading to sarcopenic obesity. Such a model will explain the promising interventions in place and invite future ones. Sarcopenic obesity is an important geriatric syndrome with significant clinical and healthcare implications. Further research is needed to harmonise definitions, clarify mechanisms contributing to syndrome and use evidence-based interventions to target biological mechanisms in both research and clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.